Evidence map›Paper›PMID 36476179›Full record

ReviewTechnology in cancer research & treatment

Role of NRF2 in Colorectal Cancer Prevention and Treatment.

Jiaxiang Li, Dan Wang, Yifei Liu, Yanhong Zhou

Open access · goldAbstract readReview
In one paragraph

Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Green-Synthesized Silver Nanoparticles fromAntioxidants (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer.International journal of molecular sciences · 2024
    Review
  11. Article
  12. Review
  13. The Antiproliferative Activity ofMolecules (Basel, Switzerland) · 2023
    Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jiaxiang LiSchool of Pharmacy, Xianning Medical College, 418442Hubei University of Science and Technology, Xianning, Hubei, China.ORCID 0000-0002-8769-0440
Dan WangSchool of Pharmacy, Xianning Medical College, 418442Hubei University of Science and Technology, Xianning, Hubei, China.
Yifei LiuSchool of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China.
Yanhong ZhouSchool of Pharmacy, Xianning Medical College, 418442Hubei University of Science and Technology, Xianning, Hubei, China.
Hubei University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear factor erythroid 2-related factor 2 (NRF2) is a basic leucine zipper protein that participates in a complex regulatory network in the body. The activation of NRF2 can prevent and treat colorectal cancer (CRC). A variety of natural compounds can activate NRF2 to inhibit oxidative stress and inflammation to prevent the occurrence and development of CRC, inhibit the proliferation of CRC cells and induce their apoptosis. However, some studies have also shown that it also has negative effects on CRC, such as overexpression of NRF2 can promote the growth of colorectal tumors and increase the drug resistance of chemotherapeutic drugs such as 5-fluorouracil and oxaliplatin. Therefore, inhibition of NRF2 can also be helpful in the treatment of CRC. In this study, we analyze the current research progress of NRF2 in CRC from various aspects to provide new ideas for prevention and treatment based on the NRF2 signaling pathway in CRC.

Indexed as

NeoplasmsHumanscolorectal cancerinflammatory-associated colorectal cancernuclear factor E2-related factor 2preventiontreatment

Identifiers

PMID36476179
PMCPMC9742687
OpenAlexW4311587112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.